LAVAL, Que. - Valeant Pharmaceuticals International, Inc. (TSX:VRX) has a deal to sell its Obagi skin care business to a Hong Kong-based group for US$190 million in cash.
The Quebec-based company, headquartered in Laval, estimates its Obagi Medical Products unit will generate about US$85 million of revenue in 2017.
The buyer is a fund managed by a limited partnership that includes China Regenerative Medicine International and Haitong International Securities Group, both headquartered in Hong Kong.
Bagikan Berita Ini
Related Posts :
TransCanada to test water in drainage ditch near spill- Asian stocks rise as Wall Street regains ground
- 87% of Canadian pot producers say industry consolidation is inevitable: survey
- Loblaw Companies shrug off industry-wide price-fixing probe, profit up from a year ago
- Ikea relaunches dresser recall after death of 7th child
0 Response to "Valeant to sell Obagi skin-care business for US$190M"
Post a Comment